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Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling 
technique for assessment of human heath risks and investigation of the toxicity. It can 
predict the target tissue dose concentration and their metabolites at target tissues. The 
currently available pharmacokinetic (PK) and pharmacodynamic (PD) data for dosing 
recommendations in patients are limited. In addition, the absorption and metabolism of 
drugs for the patients are extremely variable, and the inter-individual variability depends 
on age, race, and gender. Many PBPK models have been developed, but most of them are 
commercialized. Free PBPK models usually lack usability and flexibility, e.g., they 
require additional software support. To guide drugs dosing in various patient populations, 
a general and age-dependent PBPK model has been constructed to systematically study 
drugs metabolism and pharmacokinetics. This model includes whole-body multi-organ 
distributions, plasma protein binding, metabolism, and a scaling module. 
Parameterization of this module is based on a database of PK parameters and data 
collected from clinical experiments. The new PBPK model also has a user interface 
which is easy to learn and to use. It also provides the customization flexibility for doctors 
and researchers, such as organ selections, and communication flexibility, i.e., the XML 
storage of drugs and the patient information, and the human body setting standards. 
Results of experimentation show the model can be adapted to explore more general 
situations such as multiple dosage and other drugs.
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SECTION 1: INTRODUCTION
1.1 Background
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical 
modeling technique for assessing human health risk and investigating drugs toxicity. It 
can predict the target tissue dose concentration and their metabolites at target tissues. 
Also, it is a valuable tool for drug development and approval, risk assessment and 
research in many areas. PBPK is not a new concept; it can be traced back to the 1920s. 
Teorell [1] was the first person to describe the concepts of a PBPK model. Because 
PBPK modeling involves complex mathematical computation, including differential 
equation solving, it is hard to implement the PBPK model by hand calculation. In the 
1970s, Bischoff [2] and Brown [3] utilized computer to implement the first PBPK model 
which was applied for anticancer drugs. With the computer technology support, PBPK 
modeling has been applied in environmental assessment. Likewise, Mapleson and 
colleagues in Cardiff developed PBPK models for anesthetic agents [4], One important 
application of PBPK modeling is to predict the pharmacokinetics of a drug in humans 
based on animal data. Most of PBPK models have common characteristics. The PBPK 
model consists of physiological parameters, drug specific parameters, and the model 
structure components. Physiological parameters are defined by; organ size, blood flow, 
composition and functionality. Physiological parameters are independent of the drug. 
Drug specific parameters include protein binding, tissue affinity (partition coefficients), 
membrane permeability, and enzymatic activity.
The drug enters the organs from the arterial blood and returns to the heart in the 
venous blood. Elimination occurs in specific organs, such as kidney and liver. It is
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commonly assumed, at least for lipophilic drugs, that the uptake of drug by the tissue is 
blood-flow limited. Mass balance equations are written for each organ, and described by 
a series of differential equations.
Currently, many PBPK models have been developed. The summary of the current 
PBPK software is listed in appendix Table 1.
1.2 Problem Statement
The currently available pharmacokinetic (PK) and pharmacodynamic (PD) data for 
dosing recommendations in patients are limited. In addition, the absorption and the 
metabolism of drugs for the patients are extremely variable. The inter-individual 
variability depends on age, race, and gender. Many PBPK models have been developed, 
but most of them are commercialized (see the summary in appendix Table 1). Other free 
PBPK models lack usability and flexibility (e.g., requiring additional softweire support). 
To guide the dose administration and research, it is important to build a free and flexible 
PBPK model.
1.3 Motivation
The motivation to build a PBPK model was from my internship at the Medical 
College of Wisconsin in the summer of 2005. As a member of the PBPK model 
development team, I participated in the coding work. The purpose of that PBPK model 
was to predict the concentration of methadone in a child’s body. Since methadone was 
mostly metabolized in the liver (by enzyme CYP3A4), the metabolism model was fixed 
in the liver. The PBPK model functioned well, but was highly coupled to functions, and
too specific. It will be hard to reuse and extend. It would be interesting to build a flexible 
PBPK model by separating the mixed modules into individual modules with a less 
coupling, and each module only will do on one specific function. Further, it will be 
helpful to gain experience by applying the software design knowledge to biological 
computations. Storing the parameters in several XML formatted files, provides a solution 
to the platform-dependency problem. The main purpose of this project is to create an age- 
dependent, race and gender PBPK model, which can be used by both doctors and 
researchers.
1.4 Goal
The first goal is that this model can guide drug dosing in various patient 
populations. The second goal is the correctness of this new PBPK model. The third goal 
is to have a friendly user interface and being easy to leam and to use. The fourth goal is 
to provide customization flexibility, such as organ selections, and communication 
flexibility (i.e., the XML storage of the drug and the patient information, and human body 
setting standards). The final goal is to include computational efficiency for rapid 
feedback.
1.5 Benefits
PBPK modeling offers considerable efficiency and effectiveness in the drug 
development process, reducing both time and money required to bring a successful drug 
to market. The PBPK model aims to serve doctors and researchers related to drug or 
chemical areas. With this PBPK model, they can predict the concentration of drug
distribution more accurately, so doctors are able to give the right prescription for the 
individual patient. Researchers can do fewer animal and human studies with the help of 
this PBPK model. The use of PBPK modeling is also beneficial in predicting human 
dose-response relationships by using epidemiologic and animal data. Due to the ethical 
issues, human dosing studies during lactation are rarely available and are expensive. An 
additional benefit is that this PBPK model is a free software and anyone can use it. It 
allows users to construct PBPK modeling by simply selecting the important organs. The 
model can predict the concentrations for patients of any age.
1.6 Paper Organization
This paper is divided into five sections.
•  “Section 1 : Introduction” gives the background of PBPK, what the PBPK 
model is, why I chose this project, what benefits there are, and the goal of 
this PBPK model.
•  “Section 2: Modeling Approach and Numerical Methods” discusses the 
principle and structure of the PBPK model. Most of the paragraphs were 
spent on describing the math expressions of sub models integrated into this 
PBPK model.
•  “Section 3: PBPK Model Developments” focuses on software engineering 
design and implementation. First, it depicts the system requirements, 
architecture, data flow, GUI and XML file design, and a UML design 
diagram. Secondly, it talks about the methods in software engineering and
the core functionalities* implementations including ODE solving, optimizer 
setting, and XML implementing.
“Section 4: Results’* discusses the relationship between the volume and the 
age, model validation results, the prediction of the PBPK model, user 
interface and what new features this PBPK model includes.
“Section 5: Conclusion and Future Work” gives a general summary about 
this PBPK model and what future works should be focused on.
SECTION 2: MODELING APPROACH AND NUMERICAL METHODS
2.1 Literature Search Methods and Parameters
Before developing a PBPK model, it is necessary to gain the knowledge about the 
PBPK model from research papers. To validate the new PBPK model, the distribution 
data of drug in the human body also are important.
•  Literature search
The first literature searches were conducted by searching PubMed and Google. 
Key words were "PBPK, PBPK model development". Another way to search 
PubMed and Google is to search the references listed in the papers. If those 
papers are not available in PubMed or Google, they may be searched through 
the libraries of The Medical College of Wisconsin, University of Madison, and 
University o f Montana.
•  Experimental data collection
Methadone, fentanyl, and nevirapine are selected to validate the PBPK model. 
The concentration data and curve of those three drugs were found from the 
literature papers. Software “Scanit” was used to read the concentration and the 
time from those curves. The pharmacokinetics parameters were also added into 
the XML tables.
•  Model parameters
Two types of parameters in the PBPK model are the physiological and the 
pharmacokinetics parameters. Human physiological parameters are obtained 
from literature found by Feng (cardiac output, alveolar ventilation, blood flow
rate, tissue volume, tissue blood flow rate) in appendix Table 7. The 
pharmacokinetics parameters refer to the tissue blood partition coefficients, 
clearance, protein binding, and drug basic information. These parameters of 
Methadone, Fentanyl, and Nevirapine are listed in appendix Tables 8, 9.
2.2 The Principles of PBPK Model
The conventional PBPK model was developed to describe the pharmacokinetics of 
drugs both in blood and various body tissues. The lifecycle o f drug after administration is 
determined by the relative rates of absorption, distribution, metabolism, and elimination 
(ADME). The general disposition of drugs can be described as follows. Once the drug 
enters a vein, it is distributed into the blood circulation. When the drug enters the blood* s 
circulation, it may become bound to plasma proteins. The protein bound drug is inactive 
and cannot distribute to tissues. The drug in the vein will flow into the lungs and then 
circulate into artery. Then the total blood will be partitioned into organs or tissues. The 
dynamic equilibrium of drugs and organs is determined by the organ’s blood flow rate. If 
the drug is a substrate of enzymes in the organ, the metabolism will happen. Metabolites 
of drugs will be eliminated out the human body. Normally, this elimination occurs in the 
liver and kidney.
2.3 The Structure of PBPK Model
In the human body, there are no obvious boundaries between tissues. Most tissues 
are complex. The conventional PBPK made these assumptions summarized from the 
paper [5];
•  Only the large and essential tissues will be used in PBPK.
• Drug dissolved in each compartment.
•  Each organ is a well-mixed compartment.
•  Drug uniformly distributed.
•  Body represented by series of tissues.
•  Drug moves in and out o f tissues and is satisfied with the linear ordinary 
differential equation and conservation equation.
•  Groups o f tissues have similar blood flow and drug affinity.
•  Protein binding within the tissue happens immediately.
Considering the above assumptions, a PBPK model consisting of 14 organs or 
tissues is chosen. The detail of PBPK structure is shown in Figure 1. Each box 
corresponds to a well-mixed compartment and each arrow represents an input or output to 
the compartment determined by blood flow. The model incorporates transport processes 
and cellular metabolisms in major tissue-organ systems involved in the drug metabolism, 
distribution, and clearance. The rate of change in the amoimt of drug can be described as 
a mass balance differential equation.
2.4 The Model s Numerical Expression
To describe and predict the distribution of drug in the body, many essential sub 
models including protein binding, metabolism, transient mass balance, and scaling model 
from adult to children are integrated to the new PBPK model. The following section 
discusses these sub models in detail.
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2,4,1 Protein Binding Model
It is generally assumed that only free (unbound) drugs can produce a 
pharmacologic effect and protein bound drugs cannot metabolized and filter through the 
kidney [6]. Thus, plasma protein binding is an important factor for individual variations 
in some drug
IV
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Figure 1 : The structure of PBPK model
clearance. Small changes in the binding of highly bound drugs can cause significant 
changes in clinical response. Thus the plasma protein binding is a key model component.
Since the binding of a drug may involve 1 or 2 sites, a model of binding can be 
formulated by accounting for two non-cooperation affinities [7].
B _  n^K^P ^
F  l + K^F l + ATjF
where B  is the bound concentration of methadone, F  is the free concentration in plasma,
P  is the total protein concentration (mol/L), and K 2 are binding constants (1/ (mol/L))
and Wj and «2 are the numbers of non-competitive binding sites. Then the free fraction
of drug yh is;
F I  1
f u  — ------------ — ----------------- — ------------------------------------------- ('2,^
F  + B 1 + F / F   ̂ , fhK^P  ̂ n^K^P
1 + F ,F  I + F 2 F
If the protein binding is not saturated and only the high affinity site is considered, then 
AT, F  « 1  and
^  l  + n^K^P'
In this model, binding constants K^ and Kj  are assumed to be constants and all
protein bindings have the similar mathematic expression. Tissue protein binding is 
incorporated into a partition coefficient for each organ and/or tissue.
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2AJ2 Metabolism M odel
In drug metabolism, a variety of enzymes are involved. We assumed that the drug 
metabolism for all enzymes can use the classical Michaelis-Menten model, which is used 
to model the metabolic rate [8],
t ISFxV,^xfii^xC^ 
/C‘ + > * x C ‘ ’
where the superscript k indexes the /c-th organ in the PBPK model, C* is the total 
concentration of methadone in the metabolizing tissue in organ k (i.e. liver and intestine),
, AT* are Michaelis-Menten constants, and ISF  is the infant scaling factor used to scale
the adults to infants . Clearly, the metabolic rate depends on /h * , /5F, and intrinsic
clearance ( / K* ), which represents the intrinsic enzymatic activity of the liver.
2,4.3 M ass Balance Equation fo r  Each Organ
It is assumed that membrane transport is very rapid and transport flow is limited for 
all regions. All organs are modeled as a series of interconnected continuous stirred tank 
reactors. Nearly all organs and tissues are simulated in this PBPK model, including 
kidney, brain, GI organs, liver, spleen, muscle, lung, adipose, heart, and skin. Other 
organs are included in this model by creating an “Others” organ to group them so that the 
scaled whole-body composition reflects the entire individual [5].
Given the assumption of flow limited compartmental transport, transient mass 
balances can be written for each of the body regions considered. Specifically, mass 
balance for the pool of blood is expressed as
11
where is total cardiac output, is the arterial blood concentration of drug. is the
mixed venous concentration of drug and can be calculated from
(6)
k ^
where Q* , and P* are the volumetric blood flow, the concentration, and the partition
coefficient of the organ A:, respectively. Here, overall partition coefficients which relate 
blood and tissue concentrations are used, protein binding in tissue is assumed to be linear. 
The mass balance in compartments other than the metabolizing tissues and clearance 
tissues is given by:
= (7)
where V* is the volume of the specified organ. In these tissues, the disappearance of 
drugs is assumed to be diffusion driven and is accounted for in the above mass balance 
equation. For metabolizing tissues or clearance tissues (i.e., liver, intestine, or kidney), 
mass-balance differential equations are expressed as:
dC^ 
dt
= (8)
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where /?* is the metabolic or clearance rate in Xc-th tissue. For metabolizing tissues (i.e. 
liver and intestine), may include more than one independent metabolism term 
resulting from different enzymes.
2*4,4 Scaling Factors fo r  Age^Dependent Variability
There exist numerous PBPK models developed for a variety of drugs in adults, but 
specific PBPK models for children, especially for newborns and infants, are less well 
established. In the developmental stages, drug metabolism and disposition are 
dramatically different from those in adults. For example, some enzymes are in much 
lower levels in children than in adults, and some are even non-existent in neonates. Thus 
it is necessary to generate PBPK parameters that are appropriate for children.
Based on archival data and information in the literature, we have assembled a set of 
empirical regression functions to account for age-dependent variation in organ volume, 
blood flows, plasma protein concentrations, and enzyme activities. In choosing 
appropriate regression equations, it is preferable to use direct measurements of tissue 
parameters, to include a relatively large numbers of individuals in the data sets, and to 
have relatively high correlations between models and experimental data [9]. Particularly 
in this study, preference is given to those equations based directly on the study of infants 
and young children, rather than equations based on the adult data alone, which have to be 
extrapolated in order to predict the physiological parameters for children. The available 
regression equations have been screened and in some cases slightly modified, based on 
the results from cross-validations by ICRP (2002, http://www.irpa.net), independent 
surveys (NHANES III survey, approximately 33,994 records), IS LI human database and
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data from the literature [10] [11] [12]. In the regression equations, physiological 
parameters are usually expressed as a function of age, gender, body weight, and body 
height, as shown in appendix Table 2. Partition coefficients, Michaelis-Menten constants, 
and renal clearance are assumed to non age-dependent.
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SECTION 3: PBPK MODEL DEVELOPMENT
3.1 PBPK Model Design
When we determine the structure of the PBPK model, it is wise to consider how to 
design the software, which includes all the functionalities described before. To develop 
complex PBPK model software, the process of software engineering development 
strategy should be complied with. In the following sections, a detailed description of 
software engineering is introduced.
3.1 A  System Requirements
The system requirements are gathered from the bioengineering computation group 
at the BBC group of Medical College of Wisconsin and the interview with doctors and 
students majoring in pharmacy. All requirements are listed from high priority to low 
priority:
High priority:
•  The PBPK model can predict the distribution of drug in blood and each essential 
organ.
•  The PBPK model can simulate the concentration-time curve given the 
experimental data.
• Allow users to select organs to construct a flexibility PBPK model structure.
•  This model should include protein binding, metabolisms, scaling, infusion and 
oral dosing models.
•  This model will display the concentration versus time curve for each organ.
•  Users can turn the protein binding or metabolism model for each organ on or off.
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•  Allow users to prescribe multiple dosages to the patient.
•  XML files store the patient, drug, and standard human parameters.
•  This model should include an optimizer to adjust the target parameters by fitting 
the experimental curve.
•  This model should have an intuitive user interface.
•  This model should allow users to save the concentration curves
Low priority:
•  A web based user interface allows users to input the information of the patient 
and the drug parameters.
•  Include a drug interaction model.
•  Optimize several experimental data for a drug.
User PBPK Model
GUI
Display
Data 1/0 
Initialize
Computation
Data Storage 
XML Files
Figure 2: The system architecture consists of three tiers: User tier, PBPK Model tier, 
and XML Files storage. User tier handles inputting the data and displaying 
the data; PBPK Model will preprocess model parameters and compute the 
concentrations in each organ; XML Files will be used to store patients data, 
drug data, and human body setting parameters.
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3A .2 System  A rchitectures
From design view, using multiple tiers is a good solution for a complex product, 
which intends to be easy to extend and to reuse. The GUI tier (read and display data), the 
data controller tier (initialize data), and the core tier (computer data) are used for this new 
PBPK model. In consistency of programming language with the computation group at 
BBC, we chose Matlab to develop the PBPK model. The system architecture containing 3 
tiers is shown in Figure 2.
3.1.3 PBPK  M odel Data Flow Design
The data flow walks through four scenarios. In the first scenario, the user selects 
the patient, the drug, and the experimental data, and then the program stores these 
parameters into a structure. The second scenario mainly preprocesses reading data, 
calculates the human body setting, and scales all parameters of organs and drugs 
depending on the patient age, race, weight and height. In the third scenario, the model 
will execute the core functions of the PBPK model, which calculate the concentration for 
each organ by calling the ODE solver. The final scenario displays the concentration 
versus time curve for each organ, and also displays the pharmacokinetics of drugs in the 
main window. The detailed design is described in Figure 3.
3.1.4 G U I Design
GUI design will follow the user interface design strategies, which focus on 
usability, good feedback, and error avoiding. The main window style will be similar to 
the Microsoft Window style. It consists of four functional areas: “Menu toolbar”, “Begin 
PBPK Model”, “Parameters adjusted block” and “Display patient and drug 
pharmacokinetics”. The detail design is as follows.
17
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•  Menu bar
Five menus: File, Patient, Body Setting, Drug Setting, and Help.
•  Begin PBPK Model Area
“Begin PBPK Model Area” should provide these functions such as selecting a 
patient, selecting a drug, giving a prescription, and loading experiment data.
•  Parameters Adjusted Block
It should include the most often adjusted parameters such as the patient (age, 
race, weight, and height), the partition coefficient. Metabolism parameters Vm, 
Km, optimizer setting, and the detail adjusted for the drug and the body 
parameters.
•  Display block
It should display the patient name, the drug name, and the drug 
pharmacokinetics. The plasma concentration versus time curves will be shown 
on the pop-up window.
3.1.5 X M L  F iles Design
Four XML files (“patientData.xml”, “standardData.xml”, “drugParams.xml”, 
“controlModelData.xml”) are designed to store the patient data, the drug data, and the 
standard body setting and the control model setting. Each file consists o f a root element 
and sub elements. The detailed design can be founded in appendix Tables 3 ,4 , 5, 6.
3.1.6 PBPK  M odel M odule UM L D esign
According to the PBPK model data flow design, the UML diagram has been 
designed in Visio UML tool. Since Matlab is an interpreting language which is different
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from Java and C++ (compiling), each function has to be saved as in a Matlab file. The 
UML diagram based on files is designed, and each file in the UML diagram will only 
perform a specific functionality. The UML design diagram is shown in Figure 4.
3 ,1 .7 M ilestone Setting
Since this project has to be finished by the end of April, in order to catch the 
deadline, nine milestones are set.
•  Milestone 1: Jan. 23 — Feb. 5, read papers; understand the principles of PBPK 
Model; leam XML and find a way to parse XML file into Matlab.
•  Milestone 2: Feb. 6 — Feb. 15, implement the requirements, system architecture, 
PBPK model architecture design, XML file design, PBPK Model module UML 
design, and GUI Design.
•  Milestone 3: Feb. 16 -  Feb. 20, create the XML files and know how to read a 
XML file into Matlab.
•  Milestone 4: Feb. 21 -  Mar. 1, implement and test the basic functionalities 
including “PBPK_ODE_Solve.m”, “ODE_SET.m”, “main.m”, 
“Single_Dose_Solver.m”, ‘Tlot_Curve.m, InitDataStruct.m”.
•  Milestone 5: Mar. 2 — Mar. 8, implement functionalities including 
“CalTVector.m”, “MethadoneExpData.m”, “Optimizer_set.m”, 
“PBPK_Optimizer_Solver.m”, “Multi_Dose_Solver.m”, and 
“Optimizer_fiin. m”.
•  Milestone 6: Mar. 9 — Mar. 16, work on the scaling model coding 
(“Scale2Infant.m”), and integration testing.
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•  Milestone 7: Mar. 17 — April 20, finish writing the paper
•  Milestone 8: May 1 -  May 7, give oral presentation
3.2 Implementation
Since Matlab provides a suite of powerful tools in mathematical solutions and is 
popular language in computational research, the new PBPK model is implemented in 
Matlab. This project follows the evolutionary software development process. First, a 
working system with basic functionality was implemented, and then testing began until 
the project worked well. Second, more functionalities were added into this project, and 
started integrated model testing. The process was iterated until all methods were 
implemented. The project adhered to the milestones. GUI was implemented by the 
“Guide” tool. All source codes are attached in the appendix.
3,2,1 Softw are Engineering R ules
During the implementation, I followed these software engineering methods:
•  File creation
The main functionality was created in one file and the file name was the same as 
function name. XML file is named as “xxx.xml” format, and Matlab file is 
named as “xxx.m” format.
• Commenting
All files will have the same commenting block at the beginning of each file, 
which describes the class’s functionality, purpose, and any special notes. In 
addition, each function will be commented as to its purpose and each method 
implementation will be preceded by a comment block which describes the 
method’s functionality, parameters, and outputs, as well as other information
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described in the CS441/442 Coding and Commenting Standards. Further 
comments will be inserted to describe program flow and any other important 
aspects of the code, as being determined by the coder.
•  Coding standard
All codes will adhere to the standards set out in the aforementioned Coding and 
Commenting Standards document. All function names are capitalization 
conventions, and most variables are low capitalization at the first letter. All 
functions are using the indenting and white space.
3,2,2 Core F unctionalities Im plem entation
•  ODE solver implementation
ODE solver includes a single dosage and a multiple dosage sub model. Both 
sub models requires an ODE_SET function that computes the differential equation 
handles. The differential equations are computed in order by organ, vein->artery- 
>liver->intestine->kidney->brain->lung->muscle->adipose->heart->skin->spleen- 
>newl->others. The infusion of dose was added into a vein directly and the oral 
input was added into liver. The multiple-dosage model was implemented by calling 
ode23s solver function repeatedly. The repeated times depend on the dosage 
interval time and the lasting time. At each repeated time, the concentrations are 
passed as the initial parameters.
•  Optimizer implementation
The optimizer is an important function in this PBPK model, which can 
automatically find the best pharmacokinetics parameters by giving a good fit 
compared to the experiment data. An “error_fun” is implemented to compute the
23
error between the simulation and the experimental data in the least square. A 
number of controllers are coded which can be turned on or off in the parameters to 
optimize. The “opt_matrix” stores all parameters that attempt to optimize. A 
Matlab optimization method called “fminsearch” is used for the PBPK model.
•  XML files Implementation
The XML files are implemented from the XML design table. The XML root 
element is corresponded to the first level element in XML file table. The XML sub 
elements are related to second level elements, and so on. When the XML file is 
implemented, a testing in IE was performed. The XML parse tool box was 
downloaded from www.mathworks.com. Reading Xml file into the program was 
performed by the “xml_read” method, and by writing the data into the XML file 
was performed by the “xml_fprint” method implemented by myself.
3.2.3 User In terface Im plem entation
The user interface is implemented by “Guide” tool after all source codes done and 
tested. “Guide” Tool provides most useful widgets and a nice IDE. You can drag widgets 
into canvas and locate its place according to your design, then implement the event in the 
callback function. The “Begin PBPK Model” will be built first, then hooked into the 
PBPK model and tested it. Second, I implemented “Parmaeters Adjusted Block” area. 
Third, the display area and output figures are implemented. In addition, the menu and 
some help functions are added into the main user interface. To get a good feedback, some 
dialog boxes are integrated into the user interface.
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3.3 Testing
There are two testing methods involved in the implementation. During the 
programming, I followed the first testing method (unit testing): after a function was 
coded, a unit testing was followed. The purpose is to find whether the function worked 
and achieved the design aim. Second testing method is called the integrated testing — 
integrating many functions together and testing whether those can do the right jobs. 
When some errors were found, a debugging tool was used to debug and track where the 
problem happened. During the integrated testing, I used a number of cases to test all 
possible problems. When the problem was found, it was fixed immediately.
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SECTION 4: RESULTS
4.1 The Relationship between Organs’ Volume and Age
Organ volumes for a total of 23,028 records are calculated using the regression 
equations described in appendix Table 1. Figure 5 shows the data on body weight, body 
height, and calculated twelve organ volumes as a function of age, for the individuals 
accumulated from the above-cited databases, along with the regression fits. The results 
are comparable to the outputs from Physiological Parameters for PBPK Modeling P3M 
[9]. Blood flow rate for each organ is then calculated by multiplying the organ volume 
by its perfusion rate, which has units of volume of blood per minute per volume of organ 
[9]. With these validated scaling equations, it is possible to model inter-individual 
variation in the physiological parameters across a population of interest. Note 
correlations between age, gender, race, and body weight and body height must be 
captured in sampling the population.
Protein concentrations of albumin and ORM2 as a function of age are described by a 
simple model proposed by McNamara [12] as follows:
âlbumin infant = (0.005627 X agc + 76.7) x  in adult (9)
Q>rm2 infant = (0.01137xage + 53.4) x  Cqr ,̂2 ^  adult (10)
where the concentration of ORM2 ( Corm2 ) replaces the concentration of AAG ( ) in
the original equation given by McNamara and Alcom [12]. For enzyme activity level, 
the infant scaling factor (ISF) proposed by Alcom and McNamara [12] is used. However,
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based on the developmental data given by Stevens [13], the relative enzyme activities of 
CYP3A4 and 3A7 are updated using following equations:
ISF of enzyme CYP3A4 = 1 0 2 3 0 - 1 2 0 . 5  x age + 2310) /6 4 ,
age <21 .7  years,
ISF of enzyme CYP3A7 = 1.64 /  (age + 0.1066), age < 1 .5  years.
( 11)
(12)
where age is expressed in years. In this work, the kinetic parameters ( and ) of 
CYP3A4, 3A5, and 3A7 for metabolism of drug are assumed to be equal.
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Figure 5: The regression curve between organes volume and age. The X axis 
unit is age, and Y axis unit is volume. The red points represent 
female and the blue points represents the male.
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4.2 Model Validation Results
In order to validate this constructed PBPK model, experimental data of three drugs, 
methadone, fentanyl and nevirapine, are selected from clinical studies on adults in 
literature. These validations include the administration in oral and IV, and single and 
multiple dosages.
4.2,1 M ethadone Validation
•  Single dosage
Figure 6 shows a comparison of the PBPK model simulation versus the 
experimental data for the arterial plasma concentration of racemic methadone. The 
fitting experimental data is based on Khaeseh, E D., et al [8]. Drug dose is 0.14 
(mg/kg), IV administered in two minutes; the simulation time step is one minute, 
and the simulation is ended in 96 hours; nine organs (liver, intestine, kidney, brain, 
lung, muscle, lipid, heart, skin) were integrated into this PBPK model. An 
optimizer was used in this model to adjust the partition parameters and Michaelis- 
Menten constants (Vm, Km) in order to fit the experimental data. The mean error, 
the root error, and the correlation coefficient between the simulation and 
experiment data are 0.0005, 0.0122, and 99.46%  respectively. As seen in Figure 6 
and the above error and correlation data, the simulation curve matches the 
experimental data well.
• Multiple dosages
Figure 7 illustrates a simulation of plasma (S)-methadone based on the 
normalized data of 18 patients given a dose of 70mg/kg. The dose is
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administered orally every 24 hours. The time to achieve steady-state 
pharmacokinetics is assumed to be 10 days. The experimental data is based on 
Kharsch E.D., et al [8]. There is a 3.0 fold increase in total clearance from the 
first dose to steady-state dose. The red trend line is fitted by the addition of two 
exponential functions. It indicates that the concentration of the drug increases 
exponentially. Figure 8 shows the observed versus simulation data in the tenth 
day. The mean error, the root error, and the correlation coefficient between 
simulation and experiment data are -0.033, 0.037, and 73.57% respectively. 
These two curves fit closely. It clearly shows that the simulation curve is very 
close to experiment data and it agrees with the paper, which says in the paper 
[14]. There is a 3.5 fold increase in total clearance from the first dose and the 
steady-state dose,
A simulation of plasma methadone in blood
 Simulation
■ Exp Data
<n
30 40 50 60 70 80 90 10010 200
Time (hours)
Figure 6: Plasma concentration of methadone versus time 
after 0.06mg/kg IV dose of racemic methadone
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Figure 7: Plasma concentration of methadone versus time in the steady-state
A detail simulation of plasma (S)-Mothadono in steady-state
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Figure 8: Plasma concentration of methadone versus time in the tenth day
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Figure 9: Plasma concentration o f methadone versus time 
on multiple methadone injections of oral and IV
Figure 9 shows data analysis from Kristensen [15] on multiple methadone 
injections of different types. The experimental data was collected from patient #5 
who is given 10 mg tablet at the time 0 hour and lOmg IV at the 48th hour [15]. 
During the simulation, only the V^ax and the basic partition coefficient are adjusted.
All the other parameters are set to the population averages for individuals of the 
reported sex, height, and weight of the five patients from Kristensen, et al [15]. The 
mean error, the root error, and the correlation coefficient for R-Methadone and S- 
Methadone between the simulation and the experimental data are -0.0215, 0.0318, 
and 79.28%, and 0.0096, 0.0375, and 58.24 respectively. Figure 9 shows that there 
is a good match between the simulation and the experimental data for both (R) and 
(S)-methadone.
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A simulation of plasma fentanyl
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Figure 10: Plasma concentration of fentanyl versus time on a single dosage
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Figure 11 : Plasma concentration of nevirapine versus time on a single dosage
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4.2.2 F entanyl Validation
The pharmacokinetics of fentanyl was found from the paper [16], and Vmax and 
were based on the paper [17]. Figure 10 shows a comparison between the PBPK model 
simulation and the experimental data for the arterial plasma concentration. The fentanyl 
dosage is 0.1 mg/kg fentanyl in 2 minutes by IV administration. The mean error, the root 
error, and the correlation coefficient for Fentanyl between the simulation and the 
experimental data are -0.0579, 0.0798, and 89.43% respectively. These two curves fit 
very well except for the time period from the 5^ hour to the 12*** hour.
4.2.3 N evirapine Validation
The pharmacokinetics of nevirapine was found in the papers [18], [19]. Figure 11 
illustrates a comparison between the PBPK model simulation and the experimental data 
for the arterial plasma concentration by given 5.71 mg/kg dose in 1 minute; Model fit is 
obtained by varying the basic partition coefficient and the CYP3A4 enzyme activity 
(Vmax)- The tissue (organ) / blood partition coefficients proportions were fixed during the 
simulation. No data about Vmax and Km in literature are available in literature, thus a 
ratio of V^ax : K ^ was obtained by fitting the experimental data in the liver metabolized 
by enzyme CYP 3A4. Accordingly, Vmax and Km were calculated as 0.0001313 
nmol/min/mg protein and 10.0 umol/L. The mean error, the root error, and the 
correlation coefficient for Nevirapine between the simulation and experimental data are 
-0.0579, 0.0798, and 89.43% respectively. Figure 11 shows there is a good agreement 
between the simulation and experimental data, however, during the first couple hours, 
mismatch was observed.
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4.3 The Prediction of The PBPK Model
Figure 12 illustrates the concentration distribution of methadone in different organs. 
The parameters are the same as in Figure 6. Apparently the concentrations in each organ 
are quite different. With a close look at Figure 12, we observe that the difference in 
partition coefficients of organs is the major source for the concentration difference.
Figure 13 illustrates that the plasma concentration as a function of the time and patients 
ages. In this model the parameters are the same as in Figure 6. It clearly indicates that it is 
possible to simulate drug plasma concentration in different ages by scaling the enzyme 
Vmax, ISF and the organ volume according to the validated adult model. Figure 13 
shows the predicted concentration curve for seven male subjects aged 1, 3, 5, 10, 20, 30 
years. Figure 13 and Figure 14 show that the peak concentrations are reached after about 
1-2 hours. Given the same dosage for different age patients, the plasma concentrations of 
methadone increased linearly.
The distribution of methadone concentration in each organ
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O thers
90 100
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Figure 12: Plasma concentration of methadone versus time in each organ
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The concentration vs time in different ages
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Figure 13: Plasma concentration of methadone for different ages
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Figure 14: Plasma concentration of methadone for different ages during 0—12 hours
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Figure 14: Plasma concentration of methadone for different ages during 0—12 hours
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4.4 U ser In terface
The main window user interface is shown in Figure 15. It includes a menu toolbar, 
which allows the user to create a patient, a drug and a body setting, and edit or delete 
them. The “Begin PBPK Model” block is simple and easy to use. It includes selecting a 
patient, choosing a drug, giving a prescription, and executing this Model. A first time 
user can find the introduction by clicking the “Quick PBPK Introduction” button. During 
the modeling, the user can customize the parameters such as patient information, drug 
partition coefficient, kinetics and optimizer setting according to the pharmacokinetic of a 
drug. Finally, it can display the concentration curves in two other windows, and it can 
display the AUC and half life in the main window.
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Figure 15: PBPK Model main window
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4.5 Summary of Features
1) The PBPK model provides a set of default human body standard physiology 
parameters (organ volume, blood flows, organ weight) for patients of different 
race. Those default parameters highly reduce the user input and increase the 
efficiency.
2) The output includes both the pharmacokinetics data and the concentration curve. 
It is separated from the main program, therefore allowing user to simply save 
files.
3) It has a friendly user interface which allows users to leam and to use easily. It 
also has a fast and good feedback.
4) The model provides the flexibility for the user to build the customized model 
structure (organ selections, protein selection, enzyme selection).
5) A customized optimization function is provided, which allows users to optimize 
the parameters.
6) An age-deepened scaling module is included, which can predict a more accurate 
concentration for children.
7) The IV and Oral input module are integrated into the PBPK.
8) The whole program is built with separate module software packages, which can 
be more extendable.
9) All data sources are stored and read through the portable XML files. The XML 
files are independent of platforms and can be displayed on the web easily.
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SECTION 5: CONCLUSION AND FUTURE WORK
The distribution of drugs in the human body is complex and affected by many 
factors such as the blood flow, the permeability of membranes, the volume of tissues and 
the physicochemical characteristics of drugs. Based on the assumptions mentioned in 
Section 2, the new PBPK model has been constructed, and can perform a general purpose 
systematical drug study. It also can be adapted to explore the novel situations such as 
multiple dosages and other drugs. The developed PBPK model includes whole-body 
multi-organ distributions, plasma protein binding, metabolism, and a scaling module. The 
parameterization of this module is based on a database of PK parameters and data 
collected from clinical experiments. This new PBPK model also has a friendly user 
interface, making it easy to leam and to use. Adiditionlly, it provides customization 
flexibility such as organ selections, and communication flexibility (i.e., the XML storage 
of drug and the patient information, and the human body setting standards). The new 
PBPK model is also open source and free distribution.
This new model is still simple and does not model the urine clearance, the bonus 
input and the dm gs’ interaction. The speed of the optimizer is slow. In the future, we 
should add a drug interaction module into the new PBPK, and implement all general drug 
types administered. If possible, implementing the PBPK model on a web server would 
allow users access from the Internet. Another approach is to build a database including 
the detail pharmacokinetics for most drugs. It will reduce users’ efforts to find these data 
and save time.
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APPENDIX A; TABLES
Table 1: A list PBPK model software online
Software name Advantage Disadvantage website
AcslXtreme Classical PK, PBPK, and PD Modeling, optimization, 
graphic interface and not require explicit coding of the 
model equation
Commercial product, not open source, 
lack extendibility
http://www.aegisxcellon.com
ADAPT Simulations, non linear regression, and optimal 
sampling. Includes extended least squares and 
Bayesian optimization
No user interface input, require coding 
the model equation, require system 
support Fortran language
http://www.boomer.org/pkin/soft.html
Berkeley
Madonna
Berkeley Madonna is arguably the fastest, most 
convenient, general purpose differential equation 
solver available today.
Require coding the whole PBPK model http://www.berkeleymadonna.com/
Biokmod Biokmod can be applied for solving system of 
differential equations, fitting coefficients, convolution, 
and for modeling Linear and Nonlinear Biokinetic 
Systems.
Not complement PBPK model, solves 
simple bio-mathematic problem
http://www3.enusa.es/webMathematica/
Public/biokmod.html
JGuiB most commonly used functions of Boomer in PK/PD 
modeling included: normal fitting, simulation and 
Bayesian estimation; adjustable parameters; more 
convenient in computer-aided teaching of PK/PD 
modeling.
Not open source, hard to use. Not support 
extendibility, and no scaling 
functionality, commercial
http://jguib.pkpd.org.tw/
JavaPK for 
Desktop
Users can define their own model with population PK 
parameters using either a single-dose, integral equation 
(for the multiple-dosed) or a steady-state integral 
equation. The user defined Bayesian model can also be 
easily applied for the purpose of clinical PK or TDM.
Free software, none open source. No 
scaling functionality
http://jpkd.pkpd.org.tw/
SAAMII, Has a graphic tool for developing PBPK structures; 
Creating systems of ordinary differential equations
Commercial, not open source, lack 
extensibility, not allow good control over |
ittp://www.saam.com
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from the compartmental model structure; Permitting 
the simulation of complex experimental protocols on 
the model. Solving the model and fitting it to data 
using state-ofthe-art mathematical and statistical 
techniques.
the model equations. Not support scaling 
functionality.
WinNonlin It is a big Industry-Standard PK/PD Modeling and 
Analysis package. Not specific for PBPK model. 
Support user interface and does not require coding of 
the model functionalities.
Commercial product, not open source, not 
allows good control over the model 
equations. No support scaling 
functionality.
http://www.pharsight.com
PKQuest Provide a general purpose for PBPK model, including 
“Standardhuman” and “standardrafuser interface, 
optimizer routine. A free and open source product
It is implemented in Maple. When you 
run this product, you have to install 
Maple first. It does not include scaling 
function.
www.pkquest.com
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Table 2: A collection of regression equations to calculated organ volumes based on age, gender, body weight, and body height.
Tissue and Age Range Sex Regression Equation Sources
Blood volume (ml)
[> H ] M { l 3 . l x B H + l S . 0 5 x B W  -  480)/0.5723 Sprenger 1987
F (35.5XBH + 2.21 X B W - 3 3 S 2 ) !  0.6m Sprenger 1987
[2-14] M J  Q0.6459xlog 10( BW  )+0.002743xB//+2.1324 Linderkamp 1977
F[2-7] jQ0.6459xlogl0(BH^)+0.002743xB//+2.1324 Linderkamp 1977
F[7-14] jQ0.6412xlogl0(BW)+0.001270xBW+2.3169 Linderkamp 1977
[0-2] MF jQ0.7891xlogI0(BW)+0.004132xBH+1.8117 Linderkamp 1977
Adipose volume(ml) M (0.99 x B M I - l  .32) / 100x BW  /  0.923 x 1000 Gray 1990
F (1.20xBM/-k0.23xfl^e-5.4)/100x5W/0.923xlOOO Gray 1990
Muscle volume(ml)
[>18] M { BW xl OOO- adipose vo/wmex 0.923)x 0.54/1.04 Clarys 1984
F ( B W x l 000 -  adipose volume x 0.923) x 0.489 /1.04 Clarys 1984
[<18] M (0.0133Xfl^e-l-0.30)x(5 iy  ^lOOO-adipose W w m ex0.923)/1.04
F (0.0105X 4-0.30)X(BWx \ 0 { ^ - adipose va/«w ^x0.923)/1.04
Heart volume (ml) M 22.81x(BW/100)xBlV‘” -4.15 Ogiu 1997
F 19.99x(B///100)xBlV"^ -1.53 Ogiu 1997
Skin volume (ml)
[<1] MF BSAX618 Bailey 1996
[1-10] MF BSAX663.4 Bailey 1996
[>18] MF BSAX 1834.5X1.04 Bailey 1996
Liver volume (ml)
[>19] MF 0.05012XBW°^'XlOOO Noda 1997
[<19] M (576.9X(Bff/100) + 8.9XB1V-159.7) 71.08 Ogiu 1997
F (674.3X (BW/lOO) + 6.5XB1V-214.4)/1.08 Ogiu 1997
Spleen Volume (ml) MF 6.516X Watanabe 1997
Kidney Volume(ml)
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[>221 MF (15.4 + 2.04X5H^+ 51.8X (BH/100)^2)/1.04 Kasiske 1986
[<22] M leftKidneyWt= 10.24X (fiff/100) X +7.85;
rightKidneyWt = 9.88X (BH/100) X BlV“ ’ +7.2;
total kidney volume = (leftKidneyWt + rightKidneyWt)/L04;
Ogiu 1997
F leftKidneyWt = 10.65 X (BW/IOO) X 6.11;
rightKidneyWt = 9.88X (BH/lOO) X ’ + 6.55; 
total kidney volume = (leftKidneyWt + rightKidneyWt)/1.04;
Ogiu 1997
Brain Volume(ml) MF (1.449-3.62/fîW) X 1000/1.04; Dekaban 1978
Lung Volume (ml) M leftLungWt = 29.08X (Bm00)XgW "^+11.06;
rightLungWt = 35.47X (BW/lOO) X +5.53; 
total lung volume = (leftLungWt + rightLungWt)/1.04;
Ogiu 1997
F leftLungWt = 31.46x (BH/lOO) x B W “’ +1.43;
rightLungWt = 35.30X (Bfl/100) X BW^^+1.53; 
total lung volume = (leftLungWt + rightLungWt)/1.04;
Ogiu 1997
Pancreas Volume (ml) M (7.46X (Bff/lOO) X BIV"’ 4).79)/1.04 Ogiu 1997
F (7.92X (BB/100) X Biy"*-2.09)/1.04 Ogiu 1997
Thyroid Volume (ml) M (1.46X (BHim)  X BlV‘” -0.33)/1.04 Ogiu 1997
F (1.17X (BH/m)  X BlV®^-0.29)/1.04 Ogiu 1997
Glorgans Volume(ml) M 0.021 X (BWX1000 - adipose volumeXO.923) /1.04
F 0.027 X {BW X 1000 - adipose volume X 0.923) /1.04
* Body surface area (BSA, unit ^  ) are calculated by Mosteller formula: BSA = sqrt({BHXBW)/3600 ). 
** BMI = BW/(BH/100)^
*** All references in source column can be found in [7]
4^
Table 3: Patient data [Root: PatientDT]
Level 1 Level! Level3 Element type Note
Name [Name]
Fname
[FName] String
Lname
[LName] String
Gender
[Gender] String “F/M”
Age [Age] Integer Year
Race [Race] String
White, black, Asian, Indian, 
Arabian, etc
Height [Height] Float cm
Body weight 
[BodyWT] float __  kg
Body Surface 
area [BSA] float m^2
* [XXX] represents the element in XML file
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Table4: Anatomical parameters for a normal white male [Root: DT]
Level 1 Level2 Value Note
Basic information 
[BBasicInfo]
Body Weight [BodyWT] 70 Kg
Body Height [BodyHT] 170 Cm
Cardiac output [TotalQ] 5.8 Liters/min (5.8, 5.18)
Total Volume 
[TotalV] 85 Liters
Blood Volume [VBlood] 5.9 Percentage of body weight
Body Fat [BFat] 0.2 Fat ratio for a standard man
Body Liver WT 
[BLiverWT] 1820 g
Body Density [BDensity] 1.1 density
Body MP [BMP] 52.5
mg of microsomal protein/g 
of liver
Body ISF [BISF] 1.0 no
Body PH [BPH] 7.4 no
Gender [Gender] M Male
Race [BRace] White White
Vein [Vein]
Blood Flow [Q] 5.8 ml/min. Blood flow
Volume [V] 2.54 liter
Weight [WT] 3431 g
Extracellular fraction [Ecf] 0.5948
Water Fraction [WFract] 0.82
Density [Density] 1.06 g/cm" 3̂
Artery [Artery]
Blood Flow [Q] 5.8 ml/min. Blood flow
Volume [V] 1.59 liter
Weight [WT] 2148 g
Extracellular fraction [Ecf] 0.5948
Water Fraction [WFract] 0.82
Density [Density] 1.06 g/cm^3
Liver [Liver]
Blood Flow [Q] 1.1085 ml/min. Blood flow
Volume [V] 1.799 liter
Weight [WT] 1820 g
Extracellular fraction [Ecf] 0.23
Water Fraction [WFract] 0.7
Density [Density] 1.08 g/cm^3
Intestine [Intestine]
Blood Flow [Q] 0.822 ml/min. Blood flow
Volume [V] 0.637 liter
Weight [WT] 1175 g
Extracellular fraction [Ecf] 0.3
Water Fraction [WFract] 0.78
Density [Density] 1 g/cm*3
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Blood Flow [Q] 1.0916 ml/min. Blood flow
Volume [V] 0.28 liter
Kidney [Kidney] Weight [WT] 310 g
Extracellular fraction [Ecf] 0.165
Water Fraction [WFract] 0.8
Density [Density] 1 g/cm^3
Blood Flow [Q] 0.5905 ml/min. Blood flow
Brain
[Brain]
Volume [V] 1.4 liter
Weight [WT] 1680 6 _
Extracellular fraction [Ecf] 0.2
Water Fraction [WFract] 0.8
Density [Density] 1 g/cm^3
Blood Flow [Q] 5.8 ml/min. Blood flow
Volume [V] 0.805 liter
Lung Weight [WT] 536 g
[Lung] Extracellular fraction [Ecf] 0.2
Water Fraction [WFract] 0.8
Density [Density] 1 g/cm^3
Blood Flow [Q] 0.863 ml/min. Blood flow
Volume [V] 29.0 liter
Muscle Weight [WT] 26000 g
[Muscle] Extracellular fraction [Ecf] 0.15
Water Fraction [WFract] 0.78
Density [Density] 1 g/cm^3
Blood Flow [Q] 0.338 ml/min. Blood flow
Volume [V] 18.185 liter
Adipose Weight [WT] 17000 g
[Adipose] Extracellular fraction [Ecf] 1
Water Fraction [WFract] 0.20
Density [Density] 0.923 g/cm^3
Blood Flow [Q] 0.223 ml/min. Blood flow
Volume [V] 0.332 liter
Heart Weight [WT] 330 g
[Heart] Extracellular fraction [Ecfl 0.25
Water Fraction [WFract] 0.8
Density [Density] 1 g/cm^3
Blood Flow [Q] 0.379 ml/min. Blood flow
Volume [V] 3.1611 liter
Skin Weight [WT] 2600 g
[Skin] Extracellular fraction [Ecf] 0.60
Water Fraction [WFract] 0.70
Density [Density] 1 g/cm^3
Spleen Blood Flow [Q] 0.13 ml/min. Blood flow
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[Spleen] Volume [V] 0.13 liter
Weight [WT] 130 g _
Extracellular fraction [Ecf] 0
Water Fraction [WFract] 0
Density [Density] 1 g/cm^3
Blood Flow [Q] 0.1 ml/min. Blood flow
Volume [V] 0.1 liter
Newl Weight [WT] 0 g
[New I] Extracellular fraction [Ecf] 0
Water Fraction [WFract] 0
Density [Density] 1 g/cm'^3
Blood Flow [Q] 0.1 ml/min. Blood flow
Volume [V] 0.1 liter
Others Weight [WT] 0.1 g _
[Others] Extracellular fraction [Ecf] 0.1
Water Fraction [WFract] 0.1
Density [Density] 1.04 g/cm^3
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Table 5: Drug related PBPK parameters [Root: DrugParams]
Level 1 Level2 Levels Value Note
Drug Name [DrugName] Methadone A drug name
Drug Molecule Weight 
[DrugMolWt] 309.0 309.0 for methadone
Drug Oral bioavailability 
[DrugOralF] 0.9 Oral bioavailability
Drug Absorption rate 
[DrugAbsorptRt] 0.1 Absorption rate, min^-1
Drug VD [DrugVd] 4.5 Liters/kg
Drug PKa [DrugPka] 9.2 Liters/kg
Drug Drug Tmax [DrugTmax] 180 Hour
Basic Info 
[DrugBasi Drug Cmax [DrugCmax] 0.7314 Um/L
clnfo] Basic Partition Coefficient 
[ParCoef] 0.5
Prescription
[DrugPrespt] Dose [Dose] 0.2 mg/kg
InputType [InputType] 1
If 1 represents IV, other 2 
whiles oral (1/2)
Infuse Time [FVTime] 2 min
Lasting time 
[LastingTime] 96 hour
Interval Time [IntvlTime] 12 hour
Interval Vector Time 
[IntvlVct] 0 hour
Vein
[Vein]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 1
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
Enzyme 1 
[Enzyme 1]
SiteChoice [SiteChoice] 1
Vi, 1 represents one site, 2 
represents two sites
Kml [Kml] 9999 umol
Vml [Vml] 0 Nmol/min/mg
Km2 [Km2] 9999 umol
Vm2 [Vm2] 0 Nmol/min/mg
Infant Scaling Factor[ISF] 1
Protein 1 Name [Name] ORM2
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[Protein 1] Protein Molecule 
[ProteinMol] 23513
Have [Have] 1
0 represents no, 1 represents 
yes
Concentration [Cone] 33.33 0.78/protein_molWt* 1 e+6
SiteChoice [SiteChoice] 1
2̂, 1 represents one site, 2 
represents two sites
Binding Constant K1 [Kl] 0.152 0.38*4.0e+5/le+6
Binding Constant K2 
[K2] 0.005208 8.4*620/le+6
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor[ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0
Protein Fu 
[PFU] 0.12
Artery
[Artery]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 1
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1 ]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
2̂, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
Infant Scaling Factor [ISF] 1
Protein 1 
[Protein 1 ]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, I represents 
yes
Concentration [Cone] 6.6685 0.78/protein_moIWt* le+6
SiteChoice [SiteChoice] 1
‘/2, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 0
Binding Constant K2 
[K2] 0
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor[ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0
Protein Fu 
[PFU] 0.12
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Liver
[Liver]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 44.2
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1]
Name [Name] CYP3A4
Have [Have] 1
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
*/2, 1 represents one site, 2 
represents two sites
Kml [Kml] 10.87 umol
Vml [Vml] 0.0013 Nmol/min/mg
Km2 [Km2] 188.33 umol
Vm2 [Vm2] 0.015 Nmol/min/mg
Infant Scaling Factor[ISF] 1
Protein I 
[Protein 1]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 1
0 represents no, 1 represents 
yes
Concentration [Cone] 16.6 0.78/protein_molWt* 1 e+6
SiteChoice [SiteChoice] 1
V̂2, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 0.152
Binding Constant K2 
[K2] 0.0052
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor [ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0
Protein Fu 
[PFU] 0.12
Kidney
[Kidney]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 76.6
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1 ]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
V2, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
Infant Scaling Factor[ISF] 1
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Protein 1 
[Protein 1 ]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, I represents 
yes
Concentration [Cone] 11.6106 0.78/protein_molWt* I e+6
SiteChoice [SiteChoice] 1
V2 , 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor[ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 1
Clearance [CL] 0.023
Protein Fu 
[PFU] 0.12
Intestine
[Intestine]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 37.2
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme I ]
Name [Name] CYP3A4
Have [Have] 1
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
V̂2, 1 represents one site, 2 
represents two sites
Kml [Kml] 11.0 umol
Vml [Vml] 0.00123 Nmol/min/mg
Km2 [Km2] 1160 umol
Vm2 [Vm2] 0.0012 Nmol/min/mg
Infant Scaling Factor [ISF] I
Protein 1 
[Protein 1 ]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, I represents 
yes
Concentration [Cone] 2.234 0.78/protein_molWt* le+6
SiteChoice [SiteChoice] 1
Vz, 1 represents one site, 2 
represents two sites
Binding Constant K l [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor[ISF] 1
Clearance
[Clearance] Have Clearance [Have] 0
Clearance [CL] 0.023
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Protein Fu 
[PFU] 0.12
Brain
[Brain]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 4.6
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme I]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
‘/i, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
Infant Scaling Factor [ISF] 1
Protein 1 
[Protein 1 ]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 3.3173 0.78/protein_molWt* le+6
SiteChoice [SiteChoice] 1
Î/2, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor [ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0.023
Protein Fu 
[PFU] 0.12
Lung
[Lung]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 156.3
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
*/2, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
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Infant Scaling Factor [ISF] 1
Protein 1 
[Protein 1]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 11.6106 0.78/protein_molWt* 1 e+6
SiteChoice [SiteChoice] 1
Vi, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor [ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0.023
Protein Fu 
[PFU] 0.12
Muscle
[Muscle]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 10.5
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1 ]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
1/2, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
Infant Scaling Factor[ISF] 1
Protein! 
[Protein 1]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 16.5866 0.78/protein_molWt* 1 e+6
SiteChoice [SiteChoice] 1
Vi, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor[ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0.023
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Protein Fu 
[PFU] 0.12
Adipose
[Adipose]
Participate
[Participate] 0
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 2.95
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
V2, 1 represents one site, 2 
represents two sites
Km! [Kml] 0 umol
Vm! [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
Infant Scaling Factor[ISF] 1
Protein 1 
[Protein! ]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 11.6106 0.78/protein_molWt* le+6
SiteChoice [SiteChoice] 1
V̂2, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor[ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0
Protein Fu 
[PFU] 0.12
Heart
[Heart]
Participate
[Participate] 0
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 24
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme!
[Enzyme!]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
*/2, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
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Infant Scaling Factor [ISF] 1
Protein 1 
[Protein 1]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 16.5866 0.78/protein_mol Wt* 1 e+6
SiteChoice [SiteChoice] 1
Vi, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor[ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0.023
Protein Fu 
[PFU] 0.12
Skin
[Skin]
Participate
[Participate] 0
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 2.8
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
Vi, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
Infant Scaling Factor [ISF] 1
Protein 1 
[Protein 1 ]
Name [Name] ORM2
Protein Mo]ecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 8.0933 0.78/protein_molWt* 1 e+6
SiteChoice [SiteChoice] 1
Vi, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl ] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor [ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0.023
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Protein Fu 
[PFU] 0.12
spleen
[Spleen]
Participate
[Participate] 0
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 20
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1 ]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
16, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
Infant Scaling Factor[ISF] 1
Protein 1 
[Protein 1]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 0 0.78/protein_molWt* 1 e+6
SiteChoice [SiteChoice] 1
'/z, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor [ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0.023
Protein Fu 
[PFU] 0.12
New
[Newl]
Participate
[Participate] 0
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 1
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
*/2, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
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Infant Scaling Factor [ISF] 1
Protein 1 
[Protein 1]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 0 0.78/protein_molWt* 1 e+6
SiteChoice [SiteChoice] 1
*/2, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 
[K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor[ISF] 1
Clearance
[Clearance]
Have Clearance [Have] 0
Clearance [CL] 0.023
Protein Fu 
[PFU] 0.12
Others
[Others]
Participate
[Participate] 1
0 represents no, 1 represents 
yes
Partition Coefficient 
[PartitionCoeff] 2.87
The ratio concentration 
between vein and this organ
Permeability surface 
[PS] 0
The product of permeability 
surface area
Enzyme 1 
[Enzyme 1 ]
Name [Name] CYP3A4
Have [Have] 0
0 represents no, 1 represents 
yes
SiteChoice [SiteChoice] 1
Vi, 1 represents one site, 2 
represents two sites
Kml [Kml] 0 umol
Vml [Vml] 9999 Nmol/min/mg
Km2 [Km2] 0 umol
Vm2 [Vm2] 9999 Nmol/min/mg
Infant Scaling Factor [ISF] 1
Protein 1 
[Protein 1]
Name [Name] ORM2
Protein Molecule 
[ProteinMol] 23513
Have [Have] 0
0 represents no, 1 represents 
yes
Concentration [Cone] 0.25 0.78/protein_molWt* 1 e+6
SiteChoice [SiteChoice] 1
Vi, 1 represents one site, 2 
represents two sites
Binding Constant Kl [Kl] 9999
Binding Constant K2 [K2] 9999
Unbound fraction [Fu] 0.02 Unbound fraction
Infant Scaling Factor 
[ISF] 1
Clearance
[Clearance] Have Clearance [Have] 0
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Clearance [CL] 0.023
Protein Fu 
[PFU] 0.12
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Clearance [CL] 0.023
Protein Fu 
[PFU] 0.12
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Table 6: Optimizer control table [Root: CMDT]
Level 1 Level 2 Level2 Levels Value
Optimizer Volume Optimizer [VDT] 0
Control
[OptDT] Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Vein [Vein] Partition Coefficient Optimizer [PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Artery
[Artery]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Liver
[Liver]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Intestine
[Intestine]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Kidney
[Kidney]
Organ Weight Optimizer [WtDT] 0
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Brain Volume Optimizer [VDT] 0
[Brain] Blood Flow Optimizer [QDT] 0
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Organ Weight Optimizer [WtDT] 0
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Lung
[Lung]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Muscle
[Muscle]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Adipose
[Adipose]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Heart
[Heart]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Skin Volume Optimizer [VDT] 0
[Skin] Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
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Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Spleen
[Spleen]
Organ Weight Optimizer [WtDT] 0
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Newl
[Newl]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
Volume Optimizer [VDT] 0
Blood Flow Optimizer [QDT] 0
Organ Weight Optimizer [WtDT] 0
Others
[Others]
Partition Coefficient Optimizer 
[PtnDT] 1
Vm [VmDT] 0
Enzyme 1 [EnzymeDT] Km [KmDT] 0
Protein 1 [ProteinDT] Concentration [ProteinDT] 0
* value 0 -  no optimization set, and 1 -  optimization set
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Table 7. Anatomical parameters used in the PBPK model for a normal white male
Organ name Volume (ml) Blooc flow (ml/min)
Xp UF IF Xp UF IF
Body weight (kg) 75 1.24
Body height (cm) 177 105
veins 3431 1.05 -0.049 6445.65 1.0 -0.055
arteries 2148 1.05 -0.051 6445.65 1.0 -0.046
liver 1454 1.05 -0.092 1221.34 1.0 -0.072
kidney 318 105 -0.049 1170.11 1.0 -0.051
intestine 1175 105 -0.048 881.620 1.0 -0.058
lung 967 1.05 -0.063 6445.65 1.0 -0.047
brain 1346 105 -0.050 686.89 1.0 -0.059
spleen 139 1.05 -0.047 139.45 1.0 -0.036
muscle 30226 1.05 -0.064 906.80 1.0 -0.053
adipose 18185 1,05 0.013 363.70 1.0 0.005
heart 332 1.05 -0.062 242.51 1.0 -0.069
skin 3387 1.05 -0.051 406.46 1.0 -0.058
pancreas 109 1.05 -0.066 65.51 1.0 -0.056
thyroid 21 1.05 -0.058 106.00 1.0 -0,054
* Uncertainties associated with blood flows are assumed to be fully correlated with organ 
volumes.
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Table 8: Drug-related PBPK parameters for (R)- and (S)-methadone
Parameters (R)-methadone (S)-methadone
Xp UF IF Xp UF IF
Absorotion
bioavailability 85% 1.4 0.0443 85% 1.4 0.0443
absorption rate(min-l) 6.15e-3 2 -0.0066 6.10e-3 2 -0.0066
Protein binding
ORM2 cone [ / /m  /I] 6.6685 4 0.0585 6.6685 4 0.0585
k(ORM2) [l/( //m /L )] 0.8532 1 0 1.2432 1 0
Clearance
Knax [ /min/mg protein] 9.433e-3 5 -0.1243 2.760e-3 5 -0.091
Km [///w /L ] 198 2 0 182 2 0
urine pH 7.4 1.2 0.0216 7.4 1.2 0.021
renal clearance [ml/min] 23.0 1 0 13,2 1 0
Partition coefficients
veins 1 1 0 1 1 0
arteries 1 1 0 1 1 0
liver 15.61 3.00 -0.013 23.315 2.00 -0.025
intestine 4.104 9.00 -0.014 11.739 3.00 -0.034
kidney 6.773 12.0 -0.009 14.456 5.00 -0.003
brain 1.624 3.00 -0.013 2.5283 2.00 -0.023
lung 28.18 6.00 -0,042 56.749 3.00 -0.053
muscle 2.114 7.00 -0.033 5.59 3.00 -0.034
spleen 9.350 7.00 -0.045 23.315 3.00 -0.045
heart 4.01 3.00 -0.033 14.456 3.00 -0.033
adipose le-6 1 0 le-6 1 0
skin le-6 1 0 le-6 1 0
pancreas le-6 1 0 le-6 1 0
thyroid le-6 1 0 le-6 1 0
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Table 9: Drug-related PBPK parameters for Fentanyl and Nevirapine
Parameters Fentanyl Nevirapine
Absorotion
bioavailability 85% 85%
absorption rate(min-1 ) 6.15e-3 6.10e-3
Protein binding
ORM2 cone [ / /w  /I] 6.6685 6.6685
k(ORM2) [l/( //m /L )] 0.8532 0.8532
Clearance
Kiax [//WÏ/min/mg protein] 3.86 0.00012
Km [//m /L ] 117 10
Partition coefficients
veins 1 1
arteries 1 1
liver 20 1
intestine 20 1
kidney 60 1
brain 8 1
lung 100 1
muscle 7 1
spleen
heart 9 1
adipose 20 1
skin 7 1
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APPENDIX B: SOURCE CODE
All source code can be downloaded from http://web-dev2.cs.umt.edu/~xtong/PBPKCode. 
Under GNU General Public License, you can freely use and distribute it.
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